1. Von Willebrand factor with increased binding capacity is associated with reduced platelet aggregation but enhanced agglutination in COVID-19 patients: another COVID-19 paradox?
- Author
-
Ruberto, F., Chistolini, A., Curreli, M., Frati, G., Marullo, A. G. M., Biondi-Zoccai, G., Mancone, M., Sciarretta, S., Miraldi, F., Alessandri, F., Ceccarelli, G., Barone, F., Santoro, C., Alvaro, D., Pugliese, F., Pulcinelli, F. M., Albante, A., Antonelli, G., Araimo-Morselli, F., Auricchio, D., Bilotta, F., Brisciani, G. B. -Z. M., Bruno, K., Cappannoli, A., Cardinale, V., Celli, P., Consolo, S., Croce, C., Crocitti, B., D'Ettorre, G., De Daniela, L., De Lazzaro, F., Fedele, F., Galardo, G., Giannetti, L., Ianni, S., Imperiale, C., Maestrini, V., Magnanimi, E., Maldarelli, F., Martelli, S., Mastroianni, C., Messina, T., Pattelli, E., Pecorari, F., Perrella, S., Piazzolla, M., Portieri, M., Ratini, F., Ricci, C., Santopietro, Pietro, Tellan, G., Titi, L., Tordiglione, P., Tosi, A., and Trigilia, F.
- Subjects
Male ,Platelet Aggregation ,vonWillebrand factor ,030204 cardiovascular system & hematology ,Platelet membrane glycoprotein ,chemistry.chemical_compound ,0302 clinical medicine ,hemic and lymphatic diseases ,Platelet ,030212 general & internal medicine ,Aged, 80 and over ,biology ,Hematology ,Middle Aged ,Host-Pathogen Interactions ,Female ,Arachidonic acid ,Cardiology and Cardiovascular Medicine ,Protein Binding ,circulatory and respiratory physiology ,Adult ,Blood Platelets ,Platelets ,Agglutination ,congenital, hereditary, and neonatal diseases and abnormalities ,medicine.medical_specialty ,Platelet Function Tests ,Article ,Von Willebrand factor, reduced platelet aggregation, agglutination, COVID‑19 ,03 medical and health sciences ,Antigen ,Von Willebrand factor ,Internal medicine ,von Willebrand Factor ,medicine ,Humans ,Platelet activation ,Ristocetin ,Aged ,SARS-CoV-2 ,business.industry ,COVID-19 ,Thrombosis ,Covid 19 ,Agglutination (biology) ,Endocrinology ,chemistry ,biology.protein ,business - Abstract
Patients with Coronavirus-associated disease-2019 (COVID-19) display alterations of the hemostatic system and the presence of a prothrombotic status frequently leading to vascular complications. However, the impact of COVID-19 on platelet activity, aggregation and agglutination still needs to be clarified. We measured total levels of von Willebrand factor (vWF) and vWF binding to the platelet glycoprotein (Gp) complex (GPIb-IX-V), in a cohort of COVID-19 patients admitted to the intensive care unit of our Institution. Moreover, we evaluated platelet aggregation in response to agonists (ADP, collagen, arachidonic acid) and platelet agglutination in response to ristocetin. We found that levels of vWF antigen and the active form of vWF binding to platelets (vWF:RCo), were markedly increased in these patients. These results were associated with higher agglutination rates induced by ristocetin, thereby indirectly indicating an increased capability of vWF to bind to platelets. Conversely, we found that platelet aggregation in response to both ADP and collagen was lower in COVID-19 patients compared to healthy volunteers. This study shows that COVID-19 is associated with increased vWF-induced platelet agglutination but reduced platelet responsivity to aggregation stimuli. Our findings have translational relevance since platelet adhesion to vWF may represent a marker to predict possible complications and better delineate therapeutic strategies in COVID-19 patients. Electronic Supplementary Material The online version of this article (10.1007/s11239-020-02339-6) contains supplementary material, which is available to authorized users.
- Published
- 2021